Association of CFH, LOC387715, and HTRA1 polymorphisms with exudative age-related macular degeneration in a northern Chinese population by Xu, Yule et al.
Association of CFH, LOC387715, and HTRA1 polymorphisms with
exudative age-related macular degeneration in a northern Chinese
population
Yule Xu,1 Ning Guan,1 Jun Xu,1 Xiufen Yang,1 Kai Ma,1 Haiying Zhou,1 Feng Zhang,1 Torkel Snellingen,2 Yiqun
Jiao,2 Xipu Liu,2 Ningli Wang,1 Ningpu Liu1
(The first three authors contributed equally to this work.)
1Beijing Tongren Eye Center, Capital Medical University, Beijing, China; 2Beijing Sekwa Eye Hospital, Beijing, China
Purpose: Variants in complement factor H (CFH), the hypothetical LOC387715, and the high-temperature requirement
A-1 (HTRA1) genes have been reported to be associated with age-related macular degeneration (AMD). The purpose of
this study was to investigate the association of reported common single-nucleotide polymorphisms (SNPs) in CFH,
LOC387715, and HTRA1 with exudative AMD in a northern Chinese population.
Methods: A cohort of 121 unrelated patients with exudative AMD and 132 control subjects were enrolled in this study.
Genomic  DNA  was  extracted  from  blood  leukocytes.  Genotyping  for  SNPs  rs1061170:T>C  in  CFH  (Y402H),
rs10490924:G>T in LOC387715 (A69S), and rs11200638:G>A in the promoter of HTRA1 was performed using a
polymerase chain reaction (PCR) method followed by allele-specific restriction enzyme digestion and direct sequencing.
Results: The Y402H variant in CFH was not associated with exudative AMD in our study population. Frequencies of
Y402H was 10.3% in AMD cases and 8.0% in controls (p=0.353). Significant associations were detected for exudative
AMD with SNPs rs10490924:G>T in LOC387715 (A69S), and rs11200638:G>A in the promoter of HTRA1. The risk T-
allele frequency of rs10490924 in LOC387715 was 64.9% in cases versus 43.2% in controls (p<0.001). The odds ratio
for risk of AMD was 1.56 (95% CI; 0.80–3.03) for the GT genotype and 5.45 (95% CI; 2.59–11.49) for the TT genotype.
The A allele frequency of rs11200638 in the HTRA1 promoter was 67.8% in cases versus 42.4% in controls (p<0.001).
The odds ratio was 2.75 (95% CI; 1.34–5.64) for the GA genotype and 7.90 (95% CI; 3.61–17.26) for the AA genotype.
An odds ratio of 7.94 (95% CI; 3.49–18.04) was obtained for carriers with both TT genotype in LOC387715 and AA
genotype in the HTRA1 promoter.
Conclusions: Our data suggest that the LOC387715 and HTRA1 polymorphisms are associated with a higher risk of
exudative AMD in northern Chinese. We found no association of CFH Y402H with exudative AMD. The low frequency of
CFH Y402H variant was further confirmed in this study population.
Age-related macular degeneration (AMD) is a clinically
heterogeneous disease and the leading cause of irreversible
visual impairment in the elderly population worldwide [1,2].
The  early  stage  of  the  disease  (referred  to  as  age-related
maculopathy) is characterized by the presence of drusen with
areas of hyperpigmentation or depigmentation. As the disease
progresses,  two  types  of  late  stage  AMD  develop.  The
nonexudative  AMD  (dry  or  atrophic  type)  manifests  as
geographic  atrophy  or  sharply  demarcated  area  of
depigmentation  caused  by  atrophy  of  the  retinal  pigment
epithelium (RPE) and overlying photoreceptors. Exudative
AMD  (wet  or  neovascular  type)  occurs  when  new  blood
vessels  grow  under  the  RPE  or  between  RPE  and
neurosensory retina, leading to subretinal hemorrhage and
subsequent  scar  tissue  formation.  Both  nonexudative  and
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exudative AMD result in the loss of central vision; however,
nearly  90%  of  AMD  cases  with  severe  vision  loss  have
exudative form of AMD. The Beijing Eye Study revealed that
in Chinese older than 40 years, 2% of low vision cases and
7.7% of blindness cases were caused by AMD [3]. As this
population ages, these numbers will likely rise.
AMD  susceptibility  is  linked  to  both  genetic  and
environmental factors, although its precise etiology remains
elusive. Reported risk factors include ocular pigmentation,
dietary factors, positive family history for AMD, smoking,
and several gene mutations such as ATP-binding cassette
transporter protein 4 (ABCA4), apolipoprotein E (APOE), and
fibulin-5  (FBLN5)  [4-9].  Moreover,  genome-wide  linkage
studies  have  successfully  identified  several  major
chromosomal regions including 1q31 and 10q26 [10-14].
Recently,  the  complement  factor  H  (CFH)  gene  on
chromosome 1q31 has been demonstrated as the first major
AMD susceptibility gene, and may associate with 30%–50%
of  AMD  cases  [15-18].  The  Y402H  variant  in  exon  9
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1373(rs1061170:T>C) and other intron variants in CFH have been
reported to be associated with an increased risk of AMD in
more  than  ten  different  populations  of  European  descent
[15-23]. Susceptibility for AMD at putative genomic locus
LOC387715 on chromosome 10q26 was further confirmed in
this group [24,25]. The strongest association centered over a
frequent  coding  single-nucleotide  polymorphism  (SNP),
rs10490924:G>T in exon 1 of LOC387715 (A69S), strongly
implicating  this  gene  in  the  pathogenesis  of  AMD.
Furthermore, studies of Hong Kong Chinese and Caucasian
population  have  identified  SNP  rs11200638:G>A  in  the
promoter  of  high-temperature  requirement  A-1  (HTRA1)
gene, approximately 6.1 kb downstream of rs10490924 in
LOC387715 on chromosome 10q26, to be associated with
increased risk of AMD [26,27].
It is critical to conduct studies in different populations in
order  to  draw  firm  conclusions  about  the  role  of  genetic
factors. The purpose of this study was to investigate whether
the reported major risk alleles in the CFH, LOC387715, and
HTRA1 genes were associated with exudative AMD in our
independent cohort of northern Chinese patients.
METHODS
Patients and control individuals: Two independent groups of
Chinese individuals, including patients with exudative AMD
and control subjects, were recruited during outpatient visits to
the Beijing Tongren Hospital, Capital Medical University,
China. All cases and controls were unrelated native Chinese
from  the  greater  Beijing  area,  northern  China.  The  study
protocol was approved by the Ethics Committee of Beijing
Tongren Hospital. Informed consent was obtained from all
participants, and the procedures used conformed to the tenets
of the Declaration of Helsinki for research involving human
subjects. A total of 253 individuals, including 121 cases with
exudative AMD (71 males and 50 females) and 132 control
subjects (68 males and 64 females) participated in this study.
The age range is 50 to 90 years old with mean 66.0 and
standard deviation (SD) 8.4 in cases, and 50 to 84 years old
with mean 66.1 and SD 6.6 in controls.
Ophthalmic examination: All participants received a standard
ophthalmic  examination,  including  visual  acuity
measurement, slit-lamp biomicroscopy, and dilated fundus
examination that was performed by a retinal specialist. All
AMD patients had fluorescein as well as indocyanine green
fundus angiography. The diagnosis of exudative AMD was
based  on  ophthalmoscopic  and  fluorescein  angiographic
findings. Inclusion criteria for patients were as follows: 1) age
of 50 years or older, 2) presence of macular lesions (choroidal
neovascular  membrane,  subretinal  hemorrhage,  RPE
detachment, and fibrovascular disciform scars) in one or both
eyes; and 3) macular lesions not associated with other eye
diseases, such as degenerative myopia, angioid streaks, or any
other retinal/choroidal diseases. Controls were confirmed not
to have clinical evidence of early or late AMD in both eyes
and not to have any other eye diseases aside from mild age-
related cataracts. Subjects with severe cataracts were excluded
from the study.
DNA  extraction  and  polymerase  chain  reaction:  Blood
samples were collected from all participants and stored at -80
°C before DNA extraction. Genomic DNA was extracted from
the  peripheral  venous  blood  for  each  participant  using  a
commercially  available  genomic  DNA  extraction  and
purification kit (TIANamp Swab DNA Kit; Tiangen Biotech,
Beijing,  China)  according  to  the  manufacturer’s  protocol.
Genotyping was performed using a method of polymerase
chain reaction (PCR) followed by allele-specific restriction
enzyme  digestion  and  direct  sequencing.  The  primer
sequences  used  in  this  study  are  given  in  Table  1.  PCR
reactions  were  performed  using  a  DNA  thermocycler
(Eppendorf,  Hamburg,  Germany)  in  a  25  µl  mixture
containing 2.5 µl 10X buffer (25 mM/L MgCl2 ), 25 µM each
of  dNTP,  1  pmol  of  each  primer,  0.5  units  Taq  DNA
polymerase,  and  50  ng  genomic  DNA.  Amplification  of
HTRA1 rs11200638 was performed by adding 5% dimethyl
sulfoxide (DMSO) to the PCR reaction mixture. Samples were
denaturing at 94 °C for 5 min followed by 35 cycles under the
following conditions: denature at 94 °C for 30 s, annealing at
56 °C for 30 s, and extension at 72 °C for 45 s. The final
extension step was lengthened to 5 min. Aliquots of amplified
uncut products were resolved by electrophoresis in 2% (w/v)
agarose gels with 0.5 µg/ml ethidium bromide and visualized
under ultraviolet light. Samples were then used for allele-
specific restriction enzyme digestion. Some products were
also used for direct sequencing.
Restriction digestion and direct sequencing: The amplified
products  were  analyzed  by  restriction  enzyme  digestion
according  to  the  manufacturer’s  protocol  (New  England
Biolabs, Ipswich, MA). Enzymes used in this study and the
lengths of various restriction fragments are given in Figure 1.
Restriction digestion was performed at either 65 °C for 3 h
(Tsp509I  for  CFH  Y402H)  or  37  °C  for  3  h  (PvuII  for
LOC387715  and  EagI  for  HTRA1).  Samples  were
electrophoresed on a 2% (w/v) agarose gel with 0.5 µg/ml
ethidium  bromide.  Images  of  the  gel  were  taken  with  a
Molecular Imager Gel Doc XR System (Bio-Rad, Hercules,
TABLE. 1. PRIMERS USED IN POLYMERASE CHAIN REACTION AMPLIFICATION AND SEQUENCING
Gene SNP Primer sequence (5’→3’)
CFH rs1061170 F: TCATTGTTATGGTCCTTAGGAAA
R: GGAGTAGGAGACCAGCCATT
LOC387715 rs10490924 F: TACCCAGGACCGATGGTAAC
R: GAGGAAGGCTGAATTGCCTA
HTRA1 rs11200638 F: ATGCCACCCACAACAACTTT
R: CGCGTCCTTCAAACTAATGG
The  primer  sequences  used  in polymerase  chain reaction
(PCR)  amplification  and sequencing of the single-nucleotide
polymorphisms (SNPs) in complement factor H (CFH ),
LOC387715, and  HTRA1 genes.
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1374CA). Genotypes were determined based on the restriction
patterns and were further confirmed by direct sequencing of
the PCR products using an automatic ABI 3730XL DNA
Analyzer (Applied Biosystems, Foster City, CA) in a selected
subset of subjects (Figure 1).
Hardy    Weinberg    equilibrium    (HWE)    χ 2  values
in  cases   and  controls   were  calculated   to   identify
possible genotyping errors. Linkage disequilibrium
(LD) was measured by the D' value using statistical
software  Haploview  version  4.0  [28].  Numerical
data were examined by Student t test. Genotypes and
allele frequencies between cases and controls were
compared using the χ2 test. Odd ratios (OR) and 95%
confidence intervals (CI) were calculated according
Figure 1. Ethidium bromide-stained 2%
agarose  gels  and  direct  sequencing,
showing the PCR-restriction fragment
length  polymorphism  and
corresponding sequence chromatogram.
A: Restriction analysis for complement
factor H (CFH) Y402H polymorphism
resulted  in  digestible  fragment  (T/T),
undigestible  fragment  (C/C),  and
heterozygote  (T/C).  B:  Direct
sequencing  of  the  PCR  products
confirmed  the  restriction  patterns  for
CFH Y402H. C: Restriction analysis for
LOC387715  rs10490924  resulted  in
digestible fragment (G/G), undigestible
fragment (T/T), and heterozygote (T/G).
D: Sequencing confirmed the restriction
patterns  for  LOC387715  rs10490924.
E:  Restriction  analysis  for  HTRA1
rs11200638  resulted  in  digestible
fragment (G/G), undigestible fragment
(A/A),  and  heterozygote  (G/A).  F:
Sequencing  confirmed  the  restriction
patterns for HTRA1 rs11200638.
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1375to   the   Woolf  equation   [29].   A  p-value  of  <0.05  was
considered statistically significant.
RESULTS
Case–control  samples  were  composed  of  121  unrelated
patients  with  exudative  AMD  and  132  healthy  control
individuals (Table 2). The mean ages were 66.0±8.4 for AMD
patients  and  66.1±6.6  years  for  healthy  controls  (p=0.94,
Student t test). Percentage of males was 58.7% in the AMD
group and 51.5% in the control group (p=0.25, χ2 test).
Genotypes were determined successfully by restriction
enzyme digestion in all participants for SNPs rs1061170:T>C
in CFH (Y402H), rs10490924:G>T in LOC387715 (A69S),
and  rs11200638:G>A  in  the  promoter  region  of  HTRA1
(Table 3). Genotypes were confirmed by direct sequencing in
82 randomly selected subjects, including 40 case participants
and 42 control individuals, and the sequencing data were
consistent with the restriction enzyme digestion results in all
studied subjects. Genotype distributions for SNPs at gene loci
CFH,  LOC387715,  and  HTRA1  were  in  Hardy–Weinberg
equilibrium in either AMD cases or control subjects (p-value
≥ 0.283).
Between case participants and controls, the CFH variant
Y402H was not associated with exudative AMD (Table 3).
The frequencies for the risk C allele at Y402H were 10.3% in
AMD cases and 8.0% in controls (p=0.353, χ2 test) in the study
population.  No  significant  difference  between  the  CFH
genotypes in AMD group and control group was observed
(p=0.496, χ2 test). Compared to the wild-type homozygous TT
genotype, the OR for heterozygous TC genotype was 1.25
(95% CI; 0.65–2.40). The OR for homozygous CC genotype
was not calculated since the CC homozygote was identified
only in one case in this Chinese cohort.
A strong association with exudative AMD was detected
for SNP rs10490924:G>T in LOC387715 (Table 3). The risk
T allele frequencies were 64.9% for AMD cases and 43.2%
for controls (p<0.001, χ2 test). Genotype distributions between
AMD  cases  and  controls  were  statistically  significantly
different  (p<0.001,  χ2  test).  Compared  to  wild-type  GG
genotype, the OR for the risk of AMD was 1.56 (95% CI;
TABLE 2. AGE AND SEX OF PATIENTS WITH EXUDATIVE AMD AND CONTROL SUBJECTS
Sample
AMD cases
(n=121)
Controls
(n=132)
All subjects
(n=253) p value
Age (year) 66.0±8.4 66.1±6.6 66.0±7.5 0.94
Sex
Male 71 68 139
Female 50 64 114 0.25
The case-control samples were composed of 121 unrelated
patients  with  exudative  age-related  macular  degeneration
(AMD) and 132 control individuals. No statistical difference
was observed between AMD patients and controls groups for
age (p=0.94, Student t test) or gender (p=0.25, χ2 test).
0.80–3.03) for the heterozygous GT genotype and 5.45 (95%
CI; 2.59–11.49) for the homozygous TT genotype.
Similarly, the SNP rs11200638:G>A in the promoter of
HTRA1 was significantly associated with exudative AMD
(Table 3). Frequencies of the risk A allele were 67.8% for
AMD  cases  and  42.4%  for  controls  (p<0.001,  χ2  test).
Genotypes of this HTRA1 promoter polymorphism between
AMD  cases  and  controls  were  statistically  significantly
different (p<0.001, χ2 test). The OR was 2.75 (95% CI; 1.34–
5.64) for the heterozygous GA genotype and 7.90 (95% CI;
3.61–17.26) for the homozygous AA genotype, compared to
the wild-type GG genotype.
The LOC387715 rs10490924 and HTRA1 rs11200638
genotype combination frequencies in patients with exudative
AMD and control subjects are shown in Table 4. An OR of
7.94 (95% CI; 3.49–18.04) was obtained for carriers with
combined TT genotype of LOC387715 and AA genotype of
HTRA1  (Table  4).  LOC387715  rs10490924  and  HTRA1
rs11200638 were in high LD in cases (D’=0.98, LOD=38.09,
r2=0.843) and in controls (D’=0.869, LOD=32.55, r2=0.732).
DISCUSSION
The missense polymorphism Y402H in CFH (rs1061170) has
been identified as a common nonsynonymous variant and a
major genetic risk factor for AMD development in Caucasian
populations. Frequencies of the risk C allele in Caucasians
were between 61%–94% in AMD and 34%–46% in controls
[15-21]. In contrast, in our northern Chinese study population,
the C allele was low in frequency (10.3% in cases and 8.0%
in controls) and was not associated with exudative AMD.
Other research groups in Hong Kong and Taiwan also reported
low frequencies of the risk C allele in their study populations
[30,31]. In Hong Kong Chinese, the frequency of the risk C
allele was 5.8% in AMD cases and 3.9% in controls [30]. In
Taiwan Chinese, the frequency of the risk C allele was 11.3%
in AMD cases and 2.8% in controls [31]. Their conclusions
about  the  association  of  Y402H  with  exudative  AMD,
however,  were  controversial.  Chen  et  al.  [30]  found  no
association between the Y402H polymorphism and exudative
AMD in Hong Kong Chinese population as we did in our
study. Lau et al. [31] concluded, however, that Y402H was
significantly  associated  with  exudative  AMD  in  Taiwan
Chinese.  This  disparity  may  be  due  to  sampling  bias,
difference  in  inclusion  criteria,  demographic  factors,  or
variations  in  Chinese  subpopulations.  Nonetheless,  the
genetic attributable risk of Y402H in Chinese populations
could not be substantial because the allele frequency was low
based on the current study and the data of others [30,31].
Several  case-control  studies  in  Japanese  populations  have
shown that the Y402H variant was also at a low frequency and
not associated with AMD [32-35]. Dramatic differences may
exist  in  the  allele  frequencies  of  individual  SNPs  across
populations [36].
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1376CFH  is  involved  in  the  regulation  of  the  alternative
complement  pathway.  Complement  components  have
previously been found in drusen, an inflammatory deposit
between  retinal  pigment  epithelium  and  neuron-sensory
retina,  suggesting  dysregulation  of  complement  activation
may be involved in AMD development [37]. Recently, Laine
et al. [38] reported that the binding of the CFH Y402H variant
to C-reactive protein was strongly reduced compared to the
wild-type, indicating that the association of the CFH Y402H
with AMD could be due to reduced clearance of cellular debris
and  increased  local  inflammation.  Magnusson  et  al.  [39]
demonstrated that the Y402H variant confers a similar risk of
soft drusen and advanced forms of AMD, and hypothesized
that the Y402H variant is a major risk factor for soft drusen
formation but additional genetic as well as environmental
factors may affect progression to exudative AMD. In studies
conducted in the Chinese population, however, drusen is less
frequently observed and the prevalence of late-stage AMD has
been found to be lower when compared with Caucasians [40,
41]. The low frequency of Y402H variant and its genetic
susceptibility to AMD in our cohort as presented in this study
may correlate with the epidemiological features of AMD in
the  Chinese  population.  Similar  phenotypes  of  AMD  and
genetic  correlation  with  CFH  Y402H  variant  have  been
reported  in  Japanese  populations  [32-35,42,43].  A
relationship between ethnic differences in disease-susceptible
genetic variants and ethnic diversity in phenotypes has also
been suggested in other diseases [44-46].
In contrast to CFH Y402H variant, our data demonstrate
strong  associations  for  the  risk  of  exudative  AMD  with
LOC387715 and HTRA1 variants. Consistent with previous
published  findings  for  the  Hong  Kong  Chinese  [26]  and
Caucasian populations [27,47-49], our study shows that AMD
risk is higher with the T allele of LOC387715 rs10490924 or
the  A  allele  of  rs11200638  in  the  promoter  region  of
HTRA1. This finding is also consistent with those of Japanese
studies published recently [50-52]. The data presented here
support the hypothesis that the LOC387715 and HTRA1 genes
associate  with  susceptibility  to  AMD  development  across
diverse ethnicities. In this study, LOC387715 rs10490924 and
TABLE 3. GENOTYPE AND ALLELE FREQUENCIES IN CASES WITH EXUDATIVE AMD AND CONTROLS
Genotypes AMD cases (n=121) Controls (n=132) χ2 p value OR (95%CI)
CFH rs1061170:T>C (Y402H)
Genotype
TT 97 (80.2%) 111 (84.3%) 1.0 (reference)
TC 23 (19.0%) 21 (15.7%) 0.463 0.496 1.25 (0.65-2.40)
CC 1 ( 0.8%) 0 ( 0) - - -
H-W p=1.0 H-W p=0.843
Allele
T 217 (89.7%) 243 (92.0%) 1.0 (reference)
C 25 (10.3%) 21 ( 8.0%) 0.863 0.353 1.33 (0.73-2.45)
LOC387715 rs10490924:G>T (A69S)
Genotype
GG 18 (14.9%) 40 (30.3%) 1.0 (reference)
GT 49 (40.5%) 70 (53.0%) 1.56 (0.80-3.03)
TT 54 (44.6%) 22 (16.7%) 25.094 <0.001 5.45 (2.59-11.49)
H-W p=0.283 H-W p=0.480
Allele
G 85 (35.1%) 150 (56.8%) 1.0 (reference)
T 157 (64.9%) 114 (43.2%) 23.89 <0.001 2.43 (1.70-3.48)
HTRA1 rs11200638:G>A
Genotype
GG 13 (10.7%) 44 (33.3%) 1.0 (reference)
GA 52 (43.0%) 64 (48.5%) 2.75 (1.34-5.64)
AA 56 (46.3%) 24 (18.2%) 30.48 <0.001 7.90 (3.61-17.26)
H-W p=0.980 H-W p=1.0
Allele
G 78 (32.2%) 152 (57.6%) 1.0 (reference)
A 164 (67.8%) 112 (42.4%) 32.711 <0.001 2.82 (1.96-4.06)
This table summarizes the genotype and allele frequencies for the single-nucleotide polymorphisms (SNPs) in complement
factor H ( CFH ), LOC387715 , and  HTRA1  genes among patients with exudative age-related macular degeneration (AMD) and
control subjects. Genotype distributions for SNPs were in Hardy-Weinberg (H-W) equilibrium in either cases or controls. The
p-value  represents  comparison  or  level  of  risk  significance  between  AMD  cases  and  controls.  Adjustment  for  multiple
comparisons was made using Bonferroni method, which did not change the significant levels for all three SNPs. OR indicates
odds ratio and CI refers to confidence interval.
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1377HTRA1 rs11200638 showed similar significance levels. ORs
for exudative AMD were 1.56 (95%CI, 0.80-3.03) for the
heterozygous GT genotype and 5.45 (95%CI, 2.59-11.49) for
the homozygous TT genotypes of LOC387715 rs10490924,
when compared to the wild GG genotype. ORs for exudative
AMD with heterozygous GA genotype and homozygous AA
genotype of rs11200638 in the promoter of HTRA1 were 2.75
(95%  CI;  1.34–5.64)  and  7.90  (95%  CI;  3.61–17.26),
respectively, when compared to the wild-type GG genotype.
Individuals with both TT genotype of LOC387715 and the AA
genotype of HTRA1 associated with an OR of 7.94 (95% CI;
3.49–18.04), similar to the risk conferred by rs10490924 or
rs11200638  alone.  Based  on  the  likelihood  ratio  test,  no
interaction or combined effect was evident between the two
SNPs: rs10490924 and rs11200638.
LOC387715  and  HTRA1  are  both  located  on  the
chromosome  10q26  region,  which  is  one  of  the  major
chromosomal  regions  identified  for  AMD  susceptibility.
LOC387715  encodes  a  hypothetical  protein  of  unknown
function and is highly expressed in placental tissue, but its
expression in the human retina is weak [24]. The risk T allele
of  SNP  rs10490924  maps  to  exon  1  of  the  hypothetical
LOC387715 gene and changes putative amino acid 69 from
alanine to serine (A69S). HTRA1 encodes a heat shock serine
protease and is expressed in the mouse and human retina
[26]. SNP rs11200638 resides in the promoter of HTRA1 and
is  approximately  6.1  kb  downstream  of  the  LOC387715
rs10490924.  Because  only  a  single  cDNA  sequence  of
LOC387715  has  been  found,  DeWan  and  co-authors  [26]
hypothesized that SNP rs10490924 is a surrogate marker that
is correlated, or is in LD, with the putative AMD disease-
causing variant. They thus concluded that HTRA1 is a major
risk factor for exudative AMD. Contrary to the reports of
DeWan et al. and others [26,27], a study by Kanda et al. [53]
showed that LOC387715, but not HTRA1, represents a major
susceptibility variant for AMD at 10q26. In their study, Kanda
and  coauthors  [53]  showed  that  SNP  rs11200638  has  no
significant  impact  on  HTRA1  promoter  activity  in  three
different cell lines, and HTRA1 mRNA expression exhibits no
significantly  different  change  between  control  and  AMD
retinas. However, it has been demonstrated that LOC387715
mRNA is detected in the human retina and various cell lines
and  encodes  a  12  kDa  protein,  which  localizes  to  the
mitochondrial  outer  membrane  when  expressed  in
mammalian cells [53]. Kanda and co-authors [53] therefore
proposed that the A69S change in the LOC387715 protein
affects its presumptive function in mitochondria and enhances
the susceptibility to aging-associated degeneration of macular
photoreceptors. In agreement with previous studies, we show
in  this  study  that  LOC387715  rs10490924  and  HTRA1
rs11200638 are in high LD. Further studies are needed to
clarify  whether  LOC387715  rs10490924  and  HTRA1
rs11200638 are only in LD or are causative factors for AMD.
In summary, our data demonstrated that LOC387715 and
HTRA1, but not the CFH Y402H polymorphism, conferred
significantly increased risk for exudative AMD in a northern
Chinese  population.  Replication  of  association  studies  in
diverse  ethnic  groups  worldwide  may  provide  a  better
appreciation  of  the  genetic  contributions  in  AMD
pathogenesis. Further studies would be needed to determine
the identity of causal variant and to evaluate the possible
mechanisms through which the variant influences the disease
susceptibility.
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TABLE 4. LOC387715 RS10490924 AND HTRA1 RS11200638 GENOTYPE COMBINATION FREQUENCIES IN PATIENTS WITH EXUDATIVE AMD
AND CONTROL SUBJECTS
HTRA1
GG AG AA
AMD cases LOC387715 GG 13 (10.7%) 5 ( 4.1%) 0
TG 0 46 (38.0%) 3 ( 2.5%)
TT 0 1 ( 0.8%) 53 (43.8%)
Control subjects LOC387715 GG 37 (28.0%) 4 ( 3.0%) 0
TG 7 ( 5.3%) 58 (43.9%) 5 ( 3.8%)
TT 0 2 ( 1.5%) 19 (14.4%)
OR (95%CI) LOC387715 GG 1.0 (reference) 3.56 (0.83-15.30) -
TG - 2.26 (1.08-4.74) 1.71 (0.36-8.16)
TT - 1.42 (0.12-17.03) 7.94 (3.49-18.04)
This table shows the two-locus ( LOC387715 and HTRA1) genotype combination frequencies in patients with exudative age-
related macular degeneration (AMD) and control subjects. The combined presence of the risk  LOC387715  TT genotype and
HTRA1  AA genotype was more commonly found in cases than in controls and represented an increased risk for AMD. OR
indicates odds ratio and CI refers to confidence interval.
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